跳至主要内容
临床试验/CTIS2023-510486-10-00
CTIS2023-510486-10-00进行中(未招募)1 期

Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects

Oslo University Hospital HF0 个研究点目标入组 100 人开始时间: 2024年4月19日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • De novo, standard risk kidney (only) transplant recipients., Patients scheduled to receive tacrolimus and mycophenolate mofetil as part of their immunosuppressive therapy following transplantation (clinical decision not influenced by this study)., First kidney transplant only., Recipients of kidney from deceased or living adult donor, ABO-compatible transplantation, PRA =20%, DSA negative, Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.

排除标准

  • Pregnant or lactating female patients.

研究者

发起方
Oslo University Hospital HF

相似试验